 Cara Mack
Concepts (346)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biliary Atresia | 39 | 2024 | 224 | 11.300 |
Why?
| | Hepatitis, Autoimmune | 8 | 2022 | 33 | 4.140 |
Why?
| | Cholangitis, Sclerosing | 11 | 2022 | 75 | 4.060 |
Why?
| | Cytomegalovirus Infections | 4 | 2024 | 187 | 2.060 |
Why?
| | Cholestasis | 11 | 2022 | 228 | 2.060 |
Why?
| | Bile Ducts | 8 | 2020 | 73 | 2.000 |
Why?
| | Anemia, Aplastic | 2 | 2021 | 30 | 1.560 |
Why?
| | Hepatitis | 2 | 2021 | 46 | 1.560 |
Why?
| | Bile Ducts, Extrahepatic | 4 | 2021 | 28 | 1.450 |
Why?
| | Rotavirus Infections | 5 | 2013 | 54 | 1.400 |
Why?
| | B-Lymphocytes | 3 | 2019 | 770 | 1.260 |
Why?
| | Liver Diseases | 5 | 2022 | 282 | 1.180 |
Why?
| | Portoenterostomy, Hepatic | 9 | 2023 | 64 | 1.180 |
Why?
| | Immunosuppressive Agents | 7 | 2022 | 681 | 1.120 |
Why?
| | Elasticity Imaging Techniques | 2 | 2022 | 44 | 1.050 |
Why?
| | Liver Transplantation | 12 | 2022 | 847 | 1.030 |
Why?
| | Rotavirus | 4 | 2014 | 26 | 1.000 |
Why?
| | Autoimmunity | 7 | 2022 | 831 | 0.990 |
Why?
| | Cytokines | 7 | 2019 | 1900 | 0.920 |
Why?
| | Biliary Tract | 3 | 2019 | 17 | 0.890 |
Why?
| | Liver | 12 | 2023 | 1816 | 0.880 |
Why?
| | Immunity, Humoral | 3 | 2013 | 117 | 0.870 |
Why?
| | Azathioprine | 3 | 2022 | 51 | 0.860 |
Why?
| | Infant | 28 | 2023 | 8293 | 0.860 |
Why?
| | Liver Cirrhosis, Biliary | 2 | 2019 | 18 | 0.840 |
Why?
| | Liver Cirrhosis | 4 | 2022 | 245 | 0.830 |
Why?
| | Immunoglobulins, Intravenous | 3 | 2019 | 128 | 0.830 |
Why?
| | Immunoglobulin M | 2 | 2021 | 253 | 0.810 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2013 | 359 | 0.800 |
Why?
| | Child | 35 | 2023 | 19129 | 0.800 |
Why?
| | Autoantibodies | 3 | 2021 | 1335 | 0.780 |
Why?
| | Th1 Cells | 4 | 2013 | 133 | 0.780 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2020 | 15 | 0.740 |
Why?
| | Liver Function Tests | 4 | 2020 | 107 | 0.740 |
Why?
| | Gastroenterology | 3 | 2020 | 158 | 0.730 |
Why?
| | Disease Models, Animal | 11 | 2020 | 3730 | 0.720 |
Why?
| | Humans | 72 | 2024 | 118974 | 0.700 |
Why?
| | Antigen-Presenting Cells | 5 | 2019 | 156 | 0.690 |
Why?
| | Oligonucleotides | 1 | 2020 | 140 | 0.690 |
Why?
| | Cytomegalovirus | 3 | 2023 | 144 | 0.680 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 280 | 0.670 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2020 | 136 | 0.670 |
Why?
| | Adaptive Immunity | 3 | 2018 | 161 | 0.660 |
Why?
| | Genetic Therapy | 1 | 2020 | 267 | 0.650 |
Why?
| | Transplant Recipients | 1 | 2020 | 148 | 0.640 |
Why?
| | Thioguanine | 1 | 2017 | 20 | 0.620 |
Why?
| | Bilirubin | 8 | 2022 | 95 | 0.610 |
Why?
| | Organ Transplantation | 1 | 2020 | 165 | 0.600 |
Why?
| | Disease Outbreaks | 1 | 2020 | 322 | 0.590 |
Why?
| | Immunity, Innate | 2 | 2013 | 745 | 0.580 |
Why?
| | Cholestasis, Intrahepatic | 3 | 2022 | 43 | 0.570 |
Why?
| | Societies, Medical | 2 | 2018 | 703 | 0.560 |
Why?
| | Portal Vein | 3 | 2010 | 90 | 0.560 |
Why?
| | Hyperbilirubinemia | 3 | 2017 | 16 | 0.540 |
Why?
| | Mice, Inbred BALB C | 7 | 2018 | 1206 | 0.540 |
Why?
| | Alagille Syndrome | 3 | 2022 | 37 | 0.530 |
Why?
| | Child, Preschool | 16 | 2022 | 9491 | 0.510 |
Why?
| | Liver Circulation | 2 | 2006 | 23 | 0.510 |
Why?
| | T-Lymphocytes | 4 | 2012 | 1774 | 0.490 |
Why?
| | Inflammation | 4 | 2020 | 2566 | 0.490 |
Why?
| | Postoperative Complications | 4 | 2020 | 2235 | 0.480 |
Why?
| | Cholangitis | 2 | 2015 | 25 | 0.480 |
Why?
| | Hypertension, Portal | 3 | 2021 | 67 | 0.460 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2015 | 984 | 0.450 |
Why?
| | Animals, Newborn | 5 | 2018 | 806 | 0.440 |
Why?
| | Venous Thrombosis | 2 | 2006 | 147 | 0.440 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2015 | 702 | 0.430 |
Why?
| | Interferon-gamma | 4 | 2015 | 736 | 0.430 |
Why?
| | Reoviridae Infections | 1 | 2012 | 55 | 0.420 |
Why?
| | Vaccination | 1 | 2020 | 1222 | 0.400 |
Why?
| | Immunity, Cellular | 2 | 2012 | 270 | 0.400 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2275 | 0.390 |
Why?
| | Adolescent | 17 | 2022 | 18480 | 0.390 |
Why?
| | Infant, Newborn | 12 | 2019 | 5255 | 0.390 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 827 | 0.380 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2010 | 34 | 0.380 |
Why?
| | Hepacivirus | 1 | 2012 | 230 | 0.370 |
Why?
| | Ursodeoxycholic Acid | 2 | 2021 | 22 | 0.370 |
Why?
| | Aspartate Aminotransferases | 3 | 2022 | 95 | 0.370 |
Why?
| | Male | 27 | 2021 | 57801 | 0.360 |
Why?
| | Immunoglobulin G | 1 | 2014 | 788 | 0.360 |
Why?
| | Treatment Outcome | 11 | 2021 | 9342 | 0.360 |
Why?
| | Biomarkers | 7 | 2022 | 3588 | 0.360 |
Why?
| | Hepatitis C | 1 | 2012 | 217 | 0.350 |
Why?
| | Female | 30 | 2021 | 61565 | 0.350 |
Why?
| | Animals | 16 | 2021 | 33381 | 0.350 |
Why?
| | Mice | 12 | 2020 | 15520 | 0.340 |
Why?
| | Sarcopenia | 2 | 2021 | 72 | 0.330 |
Why?
| | Glucocorticoids | 3 | 2021 | 545 | 0.320 |
Why?
| | Cell Line | 5 | 2021 | 2707 | 0.320 |
Why?
| | Pediatrics | 5 | 2020 | 985 | 0.320 |
Why?
| | Flow Cytometry | 4 | 2018 | 1085 | 0.310 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2007 | 19 | 0.300 |
Why?
| | Failure to Thrive | 2 | 2018 | 31 | 0.300 |
Why?
| | Disease Progression | 6 | 2021 | 2490 | 0.300 |
Why?
| | Graft Rejection | 2 | 2021 | 555 | 0.300 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2014 | 1171 | 0.300 |
Why?
| | Autoimmune Diseases | 3 | 2021 | 398 | 0.300 |
Why?
| | Portal System | 2 | 2004 | 15 | 0.290 |
Why?
| | Retrospective Studies | 12 | 2022 | 12978 | 0.290 |
Why?
| | Histocompatibility Antigens | 2 | 2022 | 102 | 0.290 |
Why?
| | Macaca mulatta | 1 | 2007 | 153 | 0.280 |
Why?
| | Mesenteric Veins | 1 | 2006 | 10 | 0.280 |
Why?
| | Bile Acids and Salts | 3 | 2022 | 179 | 0.270 |
Why?
| | gamma-Glutamyltransferase | 3 | 2021 | 43 | 0.270 |
Why?
| | Epithelium | 1 | 2006 | 305 | 0.270 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2005 | 27 | 0.260 |
Why?
| | Cardiovirus Infections | 1 | 2003 | 3 | 0.240 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2004 | 53 | 0.240 |
Why?
| | Theilovirus | 1 | 2003 | 6 | 0.240 |
Why?
| | Fetal Diseases | 1 | 2005 | 148 | 0.240 |
Why?
| | Hepatopulmonary Syndrome | 2 | 2017 | 26 | 0.240 |
Why?
| | Autoantigens | 2 | 2022 | 397 | 0.240 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2003 | 25 | 0.230 |
Why?
| | Butyrates | 2 | 2022 | 54 | 0.230 |
Why?
| | Portasystemic Shunt, Surgical | 1 | 2003 | 7 | 0.230 |
Why?
| | Benzodiazepines | 2 | 2022 | 122 | 0.230 |
Why?
| | Neonatal Screening | 2 | 2015 | 152 | 0.210 |
Why?
| | Antigen Presentation | 2 | 2019 | 194 | 0.210 |
Why?
| | Hepatitis C, Chronic | 2 | 2015 | 151 | 0.210 |
Why?
| | Transaminases | 1 | 2021 | 26 | 0.210 |
Why?
| | Diagnosis, Differential | 3 | 2017 | 1384 | 0.200 |
Why?
| | Microglia | 1 | 2003 | 221 | 0.200 |
Why?
| | Transforming Growth Factor beta | 2 | 2019 | 462 | 0.200 |
Why?
| | Hepatocytes | 2 | 2020 | 205 | 0.200 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 81 | 0.200 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1691 | 0.190 |
Why?
| | Malnutrition | 1 | 2021 | 66 | 0.190 |
Why?
| | Syndrome | 1 | 2021 | 344 | 0.190 |
Why?
| | Organic Anion Transporters, Sodium-Dependent | 1 | 2020 | 28 | 0.190 |
Why?
| | Horses | 1 | 2021 | 106 | 0.190 |
Why?
| | Blood Coagulation Disorders | 1 | 2003 | 208 | 0.190 |
Why?
| | Symporters | 1 | 2020 | 53 | 0.190 |
Why?
| | Abnormalities, Multiple | 2 | 2013 | 181 | 0.190 |
Why?
| | Fluorescent Antibody Technique | 1 | 2021 | 410 | 0.180 |
Why?
| | Prednisolone | 1 | 2020 | 76 | 0.180 |
Why?
| | Vancomycin | 1 | 2021 | 79 | 0.180 |
Why?
| | Tacrolimus | 1 | 2021 | 151 | 0.180 |
Why?
| | Adoptive Transfer | 2 | 2013 | 204 | 0.180 |
Why?
| | Meta-Analysis as Topic | 1 | 2020 | 164 | 0.180 |
Why?
| | Preoperative Period | 1 | 2020 | 110 | 0.180 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2021 | 290 | 0.170 |
Why?
| | Vaccination Refusal | 1 | 2020 | 69 | 0.170 |
Why?
| | Cell Transdifferentiation | 1 | 2019 | 32 | 0.170 |
Why?
| | Colitis, Ulcerative | 1 | 2020 | 105 | 0.170 |
Why?
| | Postoperative Period | 1 | 2020 | 309 | 0.170 |
Why?
| | Cognition | 1 | 2006 | 1024 | 0.160 |
Why?
| | Drainage | 1 | 2019 | 157 | 0.160 |
Why?
| | Respiratory Tract Diseases | 1 | 2000 | 143 | 0.160 |
Why?
| | Safety | 1 | 2000 | 304 | 0.160 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2018 | 16 | 0.160 |
Why?
| | Bile Duct Diseases | 1 | 2018 | 17 | 0.160 |
Why?
| | Self Expandable Metallic Stents | 1 | 2018 | 14 | 0.160 |
Why?
| | Immunocompromised Host | 1 | 2020 | 200 | 0.160 |
Why?
| | Pruritus | 3 | 2022 | 60 | 0.160 |
Why?
| | Interleukin-2 | 3 | 2015 | 416 | 0.160 |
Why?
| | Liver Failure, Acute | 2 | 2009 | 63 | 0.150 |
Why?
| | Maintenance Chemotherapy | 1 | 2017 | 23 | 0.150 |
Why?
| | Enterohepatic Circulation | 1 | 2017 | 8 | 0.150 |
Why?
| | Alanine Transaminase | 2 | 2021 | 152 | 0.150 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 59 | 0.150 |
Why?
| | Counseling | 1 | 2000 | 353 | 0.150 |
Why?
| | Jaundice, Obstructive | 1 | 2017 | 3 | 0.150 |
Why?
| | History, 20th Century | 1 | 2018 | 281 | 0.150 |
Why?
| | Follow-Up Studies | 4 | 2019 | 4596 | 0.140 |
Why?
| | Morbidity | 1 | 2017 | 296 | 0.140 |
Why?
| | Proteins | 1 | 2022 | 938 | 0.140 |
Why?
| | Spleen | 1 | 2018 | 510 | 0.140 |
Why?
| | Digestive System Surgical Procedures | 1 | 2017 | 91 | 0.140 |
Why?
| | Virus Diseases | 2 | 2013 | 198 | 0.140 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2018 | 176 | 0.140 |
Why?
| | Cell Culture Techniques | 1 | 2018 | 356 | 0.140 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 409 | 0.140 |
Why?
| | Enterostomy | 1 | 2015 | 8 | 0.140 |
Why?
| | Models, Statistical | 1 | 2020 | 636 | 0.140 |
Why?
| | Risk Assessment | 3 | 2020 | 3057 | 0.130 |
Why?
| | End Stage Liver Disease | 1 | 2017 | 73 | 0.130 |
Why?
| | Prospective Studies | 4 | 2019 | 6471 | 0.130 |
Why?
| | Cells, Cultured | 4 | 2015 | 4077 | 0.130 |
Why?
| | Cell Separation | 2 | 2008 | 296 | 0.130 |
Why?
| | Firearms | 1 | 2000 | 281 | 0.130 |
Why?
| | Global Health | 1 | 2017 | 310 | 0.130 |
Why?
| | Biopsy | 3 | 2020 | 1079 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 521 | 0.130 |
Why?
| | Leadership | 1 | 2018 | 311 | 0.130 |
Why?
| | Preoperative Care | 1 | 2017 | 332 | 0.120 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 42 | 0.120 |
Why?
| | MicroRNAs | 1 | 2020 | 637 | 0.120 |
Why?
| | Albumins | 1 | 2014 | 100 | 0.120 |
Why?
| | Macrophages | 3 | 2005 | 1324 | 0.110 |
Why?
| | Colorectal Neoplasms | 1 | 2020 | 628 | 0.110 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 119 | 0.110 |
Why?
| | Time Factors | 5 | 2021 | 6412 | 0.110 |
Why?
| | Cholestasis, Extrahepatic | 1 | 2012 | 7 | 0.110 |
Why?
| | Risk Factors | 5 | 2021 | 9000 | 0.110 |
Why?
| | Algorithms | 1 | 2020 | 1541 | 0.110 |
Why?
| | Hepatolenticular Degeneration | 1 | 2012 | 18 | 0.110 |
Why?
| | Choledochal Cyst | 1 | 2012 | 20 | 0.110 |
Why?
| | Gallstones | 1 | 2012 | 26 | 0.110 |
Why?
| | Biliary Tract Diseases | 1 | 2012 | 35 | 0.110 |
Why?
| | Hepatitis A | 1 | 2012 | 27 | 0.110 |
Why?
| | Pregnancy | 3 | 2013 | 5691 | 0.100 |
Why?
| | Hypertension, Pulmonary | 2 | 2015 | 1794 | 0.100 |
Why?
| | Colorado | 1 | 2021 | 4196 | 0.100 |
Why?
| | Heterotaxy Syndrome | 1 | 2010 | 9 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2015 | 3171 | 0.090 |
Why?
| | Serum Albumin | 2 | 2021 | 146 | 0.090 |
Why?
| | Viral Proteins | 1 | 2012 | 296 | 0.090 |
Why?
| | Immunoblotting | 1 | 2010 | 307 | 0.090 |
Why?
| | Hemochromatosis | 1 | 2009 | 9 | 0.090 |
Why?
| | Exchange Transfusion, Whole Blood | 1 | 2009 | 18 | 0.090 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 1868 | 0.090 |
Why?
| | Prognosis | 4 | 2020 | 3443 | 0.090 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2005 | 814 | 0.090 |
Why?
| | Graft Survival | 2 | 2022 | 504 | 0.090 |
Why?
| | Internationality | 2 | 2021 | 152 | 0.080 |
Why?
| | Young Adult | 2 | 2021 | 10793 | 0.080 |
Why?
| | Epigenesis, Genetic | 1 | 2013 | 539 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2005 | 2657 | 0.080 |
Why?
| | Rats | 2 | 2007 | 5392 | 0.080 |
Why?
| | Survival Analysis | 2 | 2017 | 1267 | 0.080 |
Why?
| | Liver Failure | 1 | 2008 | 85 | 0.080 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2025 | 0.080 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2007 | 26 | 0.080 |
Why?
| | Chemokines | 1 | 2008 | 230 | 0.080 |
Why?
| | Reoviridae | 1 | 2007 | 38 | 0.080 |
Why?
| | Stem Cell Transplantation | 1 | 2008 | 153 | 0.080 |
Why?
| | Oligoclonal Bands | 1 | 2007 | 20 | 0.080 |
Why?
| | Quality of Life | 3 | 2022 | 2366 | 0.070 |
Why?
| | Immunologic Factors | 1 | 2009 | 225 | 0.070 |
Why?
| | Histocompatibility Testing | 1 | 2007 | 123 | 0.070 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2007 | 79 | 0.070 |
Why?
| | Hepatitis, Viral, Human | 1 | 2006 | 26 | 0.070 |
Why?
| | CD3 Complex | 1 | 2006 | 92 | 0.070 |
Why?
| | Virus Replication | 1 | 2008 | 405 | 0.070 |
Why?
| | Influenza A virus | 1 | 2006 | 90 | 0.070 |
Why?
| | Mice, SCID | 1 | 2006 | 333 | 0.070 |
Why?
| | Fibrosis | 2 | 2005 | 483 | 0.070 |
Why?
| | Anastomosis, Surgical | 1 | 2006 | 146 | 0.070 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2674 | 0.070 |
Why?
| | Enzyme Induction | 1 | 2005 | 94 | 0.070 |
Why?
| | Analysis of Variance | 2 | 2019 | 1293 | 0.060 |
Why?
| | Sialoglycoproteins | 1 | 2005 | 162 | 0.060 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2005 | 165 | 0.060 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1094 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2005 | 225 | 0.060 |
Why?
| | Parenteral Nutrition, Total | 1 | 2004 | 39 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 982 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2010 | 1063 | 0.060 |
Why?
| | Kupffer Cells | 1 | 2004 | 47 | 0.060 |
Why?
| | United States | 2 | 2018 | 12555 | 0.060 |
Why?
| | Protein S | 1 | 2003 | 6 | 0.060 |
Why?
| | Antithrombin III | 1 | 2003 | 7 | 0.060 |
Why?
| | Factor V | 1 | 2003 | 23 | 0.060 |
Why?
| | Prothrombin | 1 | 2003 | 21 | 0.060 |
Why?
| | Prothrombin Time | 1 | 2003 | 35 | 0.060 |
Why?
| | Factor VII | 1 | 2003 | 24 | 0.060 |
Why?
| | Paralysis | 1 | 2003 | 67 | 0.060 |
Why?
| | Partial Thromboplastin Time | 1 | 2003 | 52 | 0.060 |
Why?
| | Endoglin | 1 | 2022 | 21 | 0.060 |
Why?
| | Factor VIII | 1 | 2003 | 56 | 0.060 |
Why?
| | Mice, Inbred Strains | 1 | 2003 | 405 | 0.060 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2022 | 23 | 0.060 |
Why?
| | Protein C | 1 | 2003 | 44 | 0.060 |
Why?
| | Adult | 3 | 2020 | 31512 | 0.050 |
Why?
| | Seasons | 1 | 2005 | 461 | 0.050 |
Why?
| | Attention | 1 | 2006 | 408 | 0.050 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2003 | 79 | 0.050 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2003 | 170 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 770 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2005 | 642 | 0.050 |
Why?
| | Interleukin-8 | 1 | 2022 | 249 | 0.050 |
Why?
| | Genotype | 1 | 2007 | 1882 | 0.050 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2022 | 125 | 0.050 |
Why?
| | Cohort Studies | 3 | 2019 | 5116 | 0.050 |
Why?
| | Cholangiography | 1 | 2020 | 20 | 0.050 |
Why?
| | Neuropsychological Tests | 1 | 2006 | 1032 | 0.050 |
Why?
| | Spinal Cord | 1 | 2003 | 367 | 0.050 |
Why?
| | Drug Resistance | 1 | 2021 | 167 | 0.050 |
Why?
| | Platelet Count | 1 | 2020 | 83 | 0.050 |
Why?
| | CD79 Antigens | 1 | 2020 | 14 | 0.050 |
Why?
| | Influenza, Human | 1 | 2006 | 554 | 0.050 |
Why?
| | Fatigue | 1 | 2022 | 297 | 0.050 |
Why?
| | Protective Agents | 1 | 2020 | 42 | 0.050 |
Why?
| | Enteral Nutrition | 1 | 2021 | 170 | 0.050 |
Why?
| | Gastrointestinal Agents | 1 | 2020 | 58 | 0.050 |
Why?
| | Phenotype | 2 | 2005 | 3003 | 0.040 |
Why?
| | Propensity Score | 1 | 2021 | 242 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 300 | 0.040 |
Why?
| | Cell Movement | 1 | 2003 | 896 | 0.040 |
Why?
| | Survival Rate | 2 | 2017 | 1720 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2020 | 195 | 0.040 |
Why?
| | Cephalometry | 1 | 2018 | 28 | 0.040 |
Why?
| | Administration, Oral | 1 | 2021 | 756 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 975 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 446 | 0.040 |
Why?
| | Treatment Failure | 1 | 2019 | 341 | 0.040 |
Why?
| | Models, Biological | 1 | 2005 | 1715 | 0.040 |
Why?
| | Japan | 1 | 2017 | 97 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 842 | 0.040 |
Why?
| | Jaundice | 1 | 2017 | 15 | 0.040 |
Why?
| | Emotional Adjustment | 1 | 2017 | 18 | 0.040 |
Why?
| | Societies | 1 | 2017 | 42 | 0.040 |
Why?
| | Postoperative Care | 1 | 2018 | 237 | 0.040 |
Why?
| | Reference Values | 1 | 2018 | 774 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2017 | 190 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2018 | 272 | 0.040 |
Why?
| | Family Relations | 1 | 2017 | 85 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2020 | 726 | 0.030 |
Why?
| | North America | 1 | 2017 | 266 | 0.030 |
Why?
| | Europe | 1 | 2017 | 356 | 0.030 |
Why?
| | Hemorrhage | 1 | 2000 | 623 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 649 | 0.030 |
Why?
| | Apoptosis | 1 | 2005 | 2484 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2015 | 95 | 0.030 |
Why?
| | Waiting Lists | 1 | 2017 | 228 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 2015 | 209 | 0.030 |
Why?
| | Mutation | 1 | 2005 | 3457 | 0.030 |
Why?
| | Pneumonia | 1 | 2000 | 592 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2018 | 1687 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 2995 | 0.030 |
Why?
| | Child Development | 1 | 2018 | 410 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1125 | 0.030 |
Why?
| | Body Weight | 1 | 2018 | 934 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2015 | 197 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2020 | 2680 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 333 | 0.030 |
Why?
| | Registries | 1 | 2021 | 1810 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1474 | 0.030 |
Why?
| | Lung Diseases | 1 | 2000 | 718 | 0.030 |
Why?
| | Parents | 1 | 2000 | 1212 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 2874 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2015 | 1067 | 0.030 |
Why?
| | Brain | 1 | 2003 | 2490 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2020 | 2445 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2017 | 781 | 0.020 |
Why?
| | Dilatation, Pathologic | 1 | 2010 | 56 | 0.020 |
Why?
| | Osteopontin | 1 | 2005 | 39 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2005 | 268 | 0.020 |
Why?
| | Patient Selection | 1 | 2008 | 676 | 0.020 |
Why?
| | Genomic Imprinting | 1 | 2004 | 32 | 0.020 |
Why?
| | Influenza Vaccines | 1 | 2006 | 500 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2159 | 0.010 |
Why?
| | Cell Cycle Proteins | 1 | 2004 | 565 | 0.010 |
Why?
| | Gene Expression | 1 | 2005 | 1489 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2005 | 963 | 0.010 |
Why?
|
|
Mack's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|